DOVER, Del., Oct. 13, 2025 /PRNewswire/ — Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors targeting escape mutations in hematologic malignancies and solid tumors, today announced the presentation of data for its brain- and lung-permeable pan-EGFR inhibitor, ZE77-0273 is a reversible small-molecule drug candidate that demonstrates broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC), a high selectivity index versus wild-type EGFR, and a wide therapeutic window characterized by excellent safety and tolerability.
About Eilean Therapeutics
Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and solid tumors. Utilizing its proprietary hybrid AI/ML drug design platform, the company leverages proprietary partner data, advanced chem/bio tools, and deep domain expertise to identify highly valuable molecular targets, accelerate drug discovery, and optimize the development of highly differentiated therapies.
Eilean’s oncology programs for therapy-resistant lung cancer include best-in-class reversible pan-EGFR inhibitor, c-Met inhibitor, and pan-KRAS molecular glue.
For more information, visit www.eileanther.com
Media Contact:
Amy Burd, PhD, CSO
Eilean Therapeutics, Inc.
Email: [email protected]
SOURCE Eilean Therapeutics
